Skip to content
Menu

4D Molecular Therapeutics, Inc. FDMT

Full chart Compare
Set alert

Price alert · FDMT

All alert types
10.72 USD +0.26 (+2.49%)

Regular-session close

10.73 +0.01 +0.09%

After hours · Nov 19, 5:55 PM ET

10.40 Day range 11.02
6.96 52-week range 16.93
YTD
+42.93%
1 year
-0.74%

5D -1.94 (-15.26%)

111213WedThuFriMonTue10.77
Market cap
604.39M
Revenue (ttm)
17.00K
EPS (ttm)
-2.70
Shares out
46.23M
Forward P/E
-1.79
YTD return
+42.93%
1-year return
-0.74%
50-day average
7.82
Volume
755.23K
Avg volume
984.18K
Open
10.97
Previous close
10.46
Day's range
10.40 – 11.02
52-week range
6.96 – 16.93
Analysts
Buy
Price target
42.64 (+297.7%)

Key statistics

200-day average
17.94
Price / sales
15989.35
Price / book
0.82
Revenue growth
-100.00%
Short % of float
19.19%

Fundamental scorecard

9 of 25 checks passed on FDMT’s reported financials

ValueGrowthProfitabilityHealthDividend

9of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
FDMT Revenue — quarterly 4.14M
FDMT Net income — quarterly -78.06M
FDMT EPS — quarterly -1.08

Earnings

FDMT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.67-0.79-0.12-17.91%
Aug 8, 2024Jun 1, 2024-0.72-0.63+0.09+12.50%
Aug 8, 2024Jun 1, 2024-0.72———
May 9, 2024Mar 1, 2024-0.73-0.66+0.07+9.59%
May 9, 2024Mar 1, 2024-0.73———
Feb 29, 2024Dec 1, 2023-0.68-0.77-0.09-13.24%

Upgrades / downgrades

FDMT analyst upgrades and downgrades
DateFirmActionFromTo
Dec 18, 2024B of A SecuritiesmainBuyBuy
Nov 21, 2024Morgan Stanleyinit—Underweight
Nov 14, 2024Chardan CapitalmainBuyBuy
Nov 14, 2024HC Wainwright & Co.reitBuyBuy
Nov 14, 2024RBC CapitalmainOutperformOutperform
Sep 23, 2024Cantor FitzgeralddownOverweightNeutral

About 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on FDMT — it syncs with the Stock Master app.

Insider holders

FDMT insider holders
InsiderRelationLatest transactionDateShares held
BIZILY SCOTTOfficerSaleSep 15, 20246,781
CHACKO JACOB MDirectorSaleApr 20, 20230
KIM ROBERT YOUNGOfficerSaleFeb 4, 20241,043
KIRN DAVIDChief Executive OfficerSaleJul 9, 20241,059,150
MORETTI AUGUST JChief Financial OfficerConversion of Exercise of derivative securityMay 14, 202311,045
VIKING GLOBAL INVESTORS LPBeneficial Owner of more than 10% of a Class of SecuritySaleJan 3, 20240

Institution ownership

FDMT institution ownership
Holder% heldSharesValueReported
BVF Inc.15.97%7,382,64243.41MSep 29, 2024
RA Capital Management, L.P.11.03%5,098,21129.98MSep 29, 2024
Blackrock Inc.10.53%4,868,78928.63MSep 29, 2024
VR Adviser, LLC9.52%4,400,00025.87MSep 29, 2024
Deep Track Capital, Lp8.86%4,096,45224.09MSep 29, 2024
Goldman Sachs Group Inc7.77%3,591,03021.12MSep 29, 2024

Fund ownership

FDMT fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund3.33%1,537,3689.04MSep 29, 2024
iShares Russell 2000 ETF2.83%1,308,5527.69MOct 30, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.25%1,038,5056.11MSep 29, 2024
Janus Henderson Global Life Sciences Fund2.20%1,016,2355.98MSep 29, 2024
Vanguard Extended Market Index Fund1.27%589,2743.46MSep 29, 2024
Fidelity Small Cap Index Fund1.10%509,9653.00MAug 30, 2024